Last reviewed · How we verify
Auxiliary Medicinal Product - Dexamethasone
Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Auxiliary treatment for management of inflammation and immune-related adverse events in cancer therapy, Supportive care in phase 3 oncology trials (specific indication dependent on parent trial).
At a glance
| Generic name | Auxiliary Medicinal Product - Dexamethasone |
|---|---|
| Sponsor | MedSIR |
| Drug class | Glucocorticoid (corticosteroid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Oncology (supportive care) |
| Phase | Phase 3 |
Mechanism of action
Dexamethasone acts as a potent corticosteroid that decreases immune cell activation, reduces production of inflammatory mediators (cytokines, chemokines), and stabilizes cell membranes. It is commonly used as an auxiliary agent in oncology trials to manage treatment-related toxicities, particularly immune-related adverse events and inflammation associated with cancer therapies.
Approved indications
- Auxiliary treatment for management of inflammation and immune-related adverse events in cancer therapy
- Supportive care in phase 3 oncology trials (specific indication dependent on parent trial)
Common side effects
- Hyperglycemia
- Immunosuppression / increased infection risk
- Insomnia
- Mood changes
- Hypertension
- Osteoporosis (with chronic use)
Key clinical trials
- Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. (PHASE3)
- Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma (PHASE3)
- SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM (PHASE3)
- Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Auxiliary Medicinal Product - Dexamethasone CI brief — competitive landscape report
- Auxiliary Medicinal Product - Dexamethasone updates RSS · CI watch RSS
- MedSIR portfolio CI